EGFR/HER 受体的综合分析用于妇科癌症的个体化治疗。
Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.
机构信息
Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, 52242, USA,
出版信息
Mol Diagn Ther. 2014 Apr;18(2):137-51. doi: 10.1007/s40291-013-0070-3.
Abstract
The primary gynecologic cancers include cancers of the endometrium, ovary, and cervix. Worldwide, cervical cancer is the most common gynecologic cancer, whereas endometrial cancer is the most common in the US. Ovarian cancer is the fifth most deadly cancer in women, with 5-year survival rates for advanced disease at only 27 %. As such, there is an urgent need for reliable screening tools and novel targeted therapeutic regimens for these malignancies. The epidermal growth factor receptor (EGFR)/human EGFR (HER) family of receptors has been associated with the development and progression of many solid tumors. Despite clear roles for these receptors in other cancers, the expression of HER family members in gynecologic cancers and their relationship with disease stage, grade, and response to treatment remain controversial. In this review, we describe the existing evidence for the use of HER family members as diagnostic and prognostic indicators as well as their potential as therapeutic targets in gynecologic cancers.
摘要
原发性妇科癌症包括子宫内膜癌、卵巢癌和宫颈癌。在全球范围内，宫颈癌是最常见的妇科癌症，而子宫内膜癌是美国最常见的妇科癌症。卵巢癌是女性第五大最致命的癌症，晚期疾病的 5 年生存率仅为 27%。因此，迫切需要可靠的筛查工具和新的针对这些恶性肿瘤的靶向治疗方案。表皮生长因子受体 (EGFR)/人表皮生长因子受体 (HER) 受体家族与许多实体肿瘤的发生和发展有关。尽管这些受体在其他癌症中具有明确的作用，但 HER 家族成员在妇科癌症中的表达及其与疾病分期、分级和治疗反应的关系仍存在争议。在这篇综述中，我们描述了将 HER 家族成员用作诊断和预后指标的现有证据，以及它们作为妇科癌症治疗靶点的潜力。
相似文献
1
Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.EGFR/HER 受体的综合分析用于妇科癌症的个体化治疗。
Mol Diagn Ther. 2014 Apr;18(2):137-51. doi: 10.1007/s40291-013-0070-3.
2
Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.表皮生长因子受体抑制剂在妇科恶性肿瘤中的理论依据及临床经验
Curr Treat Options Oncol. 2005 Mar;6(2):103-14. doi: 10.1007/s11864-005-0018-x.
3
F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies.F84，一种喹唑啉衍生物，对人类妇科恶性肿瘤表现出高抗肿瘤活性。
Invest New Drugs. 2010 Apr;28(2):132-8. doi: 10.1007/s10637-009-9225-9. Epub 2009 Feb 12.
4
Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.将精准医学融入妇科肿瘤的当代管理中。
Curr Oncol Rep. 2022 Jul;24(7):889-904. doi: 10.1007/s11912-021-01163-2. Epub 2022 Mar 26.
5
The role of the HER-2/neu oncogene in gynecologic cancers.HER-2/neu癌基因在妇科癌症中的作用。
J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105.
6
The roles of pathology in targeted therapy of women with gynecologic cancers.病理学在妇科癌症女性靶向治疗中的作用。
Gynecol Oncol. 2018 Jan;148(1):213-221. doi: 10.1016/j.ygyno.2017.11.020. Epub 2017 Nov 23.
7
Targeted therapies in gynecologic cancers.妇科癌症的靶向治疗
Curr Cancer Drug Targets. 2006 Jun;6(4):333-63. doi: 10.2174/156800906777441799.
8
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.妇科癌症患者源性肿瘤细胞的药物基因组学分析。
Genome Biol. 2019 Nov 26;20(1):253. doi: 10.1186/s13059-019-1848-3.
9
Personalized therapy in gynecological cancer: a reality in clinical practice?妇科癌症的个性化治疗：临床实践中的现实情况？
Curr Oncol Rep. 2013 Jun;15(3):201-3. doi: 10.1007/s11912-013-0314-8.
10
Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.个性化循环肿瘤DNA生物标志物可动态预测妇科癌症的治疗反应和生存情况。
PLoS One. 2015 Dec 30;10(12):e0145754. doi: 10.1371/journal.pone.0145754. eCollection 2015.
引用本文的文献
1
Ligand-Based CAR-T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies.靶向表皮生长因子受体的基于配体的嵌合抗原受体T细胞对妇科恶性肿瘤显示出良好的抗肿瘤作用。
Cancer Sci. 2025 Aug;116(8):2243-2255. doi: 10.1111/cas.70106. Epub 2025 May 19.
2
SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer progression.SPTLC2驱动EGFR-FAK-HBEGF信号轴以促进卵巢癌进展。
Oncogene. 2025 Mar;44(10):679-693. doi: 10.1038/s41388-024-03249-0. Epub 2024 Dec 7.
3
Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy.子宫内膜癌的新型分子靶点：治疗机制与前景
Biologics. 2024 Mar 21;18:79-93. doi: 10.2147/BTT.S369783. eCollection 2024.
4
Why Does Your Uterus Become Malignant? The Impact of the Microbiome on Endometrial Carcinogenesis.你的子宫为何会发生癌变？微生物群对子宫内膜癌发生的影响。
Life (Basel). 2023 Nov 28;13(12):2269. doi: 10.3390/life13122269.
5
The ErbB Signaling Network and Its Potential Role in Endometrial Cancer.表皮生长因子受体（ErbB）信号网络及其在子宫内膜癌中的潜在作用
Epigenomes. 2023 Oct 1;7(4):24. doi: 10.3390/epigenomes7040024.
6
[Diabetes mellitus and the female reproductive system tumors].[糖尿病与女性生殖系统肿瘤]
Probl Endokrinol (Mosk). 2023 Jun 30;69(3):103-110. doi: 10.14341/probl13282.
7
The role of GnRH metabolite, GnRH-(1-5), in endometrial cancer.GnRH 代谢产物 GnRH-(1-5) 在子宫内膜癌中的作用。
Front Endocrinol (Lausanne). 2023 Apr 14;14:1183278. doi: 10.3389/fendo.2023.1183278. eCollection 2023.
8
BaySyn: Bayesian Evidence Synthesis for Multi-system Multiomic Integration.BaySyn：多系统多组学整合的贝叶斯证据综合。
Pac Symp Biocomput. 2023;28:275-286.
9
Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?靶向卵巢癌中的酪氨酸激酶：小分子抑制剂和单克隆抗体，我们目前进展如何？
Biomedicines. 2022 Aug 29;10(9):2113. doi: 10.3390/biomedicines10092113.
10
Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.基于其激酶非依赖性功能对癌症中表皮生长因子受体（EGFR）的重新思考
Front Oncol. 2019 Aug 23;9:800. doi: 10.3389/fonc.2019.00800. eCollection 2019.
本文引用的文献
1
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53.分子增强化疗策略在具有突变型p53的子宫内膜肿瘤中实现合成致死效应
Obstet Gynecol Int. 2013;2013:828165. doi: 10.1155/2013/828165. Epub 2013 Dec 7.
2
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.一项评估吉非替尼治疗持续性或复发性子宫内膜癌的 II 期临床试验：一项妇科肿瘤学组研究。
Gynecol Oncol. 2013 Jun;129(3):486-94. doi: 10.1016/j.ygyno.2013.02.019. Epub 2013 Feb 21.
3
HER3 overexpression and survival in solid tumors: a meta-analysis.HER3 过表达与实体瘤患者生存：荟萃分析
J Natl Cancer Inst. 2013 Feb 20;105(4):266-73. doi: 10.1093/jnci/djs501. Epub 2012 Dec 8.
4
Activating HER2 mutations in HER2 gene amplification negative breast cancer.在 HER2 基因扩增阴性乳腺癌中激活 HER2 突变。
Cancer Discov. 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012 Dec 7.
5
Advances in Targeting HER3 as an Anticancer Therapy.靶向HER3作为抗癌疗法的进展
Chemother Res Pract. 2012;2012:817304. doi: 10.1155/2012/817304. Epub 2012 Nov 7.
6
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.用非功能性 p53 绕过 G2/M 检查点诱导子宫内膜癌细胞有丝分裂细胞死亡。
Gynecol Oncol. 2013 Mar;128(3):461-9. doi: 10.1016/j.ygyno.2012.11.004. Epub 2012 Nov 9.
7
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.在肺癌中对受体酪氨酸激酶突变的功能分析确定了 ERBB2 的致癌细胞外结构域突变。
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. doi: 10.1073/pnas.1203201109. Epub 2012 Aug 20.
8
Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.肽疫苗和针对 HER 和 VEGF 蛋白的靶向治疗可能为癌症免疫治疗提供一个潜在的新模式。
Future Oncol. 2012 Aug;8(8):961-87. doi: 10.2217/fon.12.95.
9
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.在一项妇科肿瘤学组关于持续性或复发性子宫内膜癌的 II 期临床试验中，拉帕替尼和 EGFR 突变的潜在预后价值。
Gynecol Oncol. 2012 Nov;127(2):345-50. doi: 10.1016/j.ygyno.2012.07.127. Epub 2012 Aug 7.
10
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.表皮生长因子受体作为上皮性卵巢癌的治疗靶点。
Cancer Epidemiol. 2012 Oct;36(5):490-6. doi: 10.1016/j.canep.2012.06.005. Epub 2012 Jul 20.
Zotero 插件